Skip to main content
. 2023 Apr 3;11(4):786. doi: 10.3390/vaccines11040786

Figure 2.

Figure 2

Concordance between cellular and humoral responses. Black dots indicate patients who developed a protective humoral response. Red dots indicate patients who did not develop a protective humoral response. Dotted line marks IFN-γ levels of 80 pg/mL that were considered positive. ALEM: alemtuzumab; CLAD: cladribine; FING: fingolimod; FLT: first-line therapies; NATA: natalizumab; NTP: non-treated patients; OCRE: ocrelizumab; RITU: rituximab.